Non‐Responders to Biologic Disease Modifying Antirheumatic Treatment for Inflammatory Bowel Diseases

Svetla Gadzhanova, Elizabeth Roughead, Jasbir Arora (RSS) · 2025

Read Non‐Responders to Biologic Disease Modifying Antirheumatic Treatment for Inflammatory Bowel Diseases by Svetla Gadzhanova, Elizabeth Roughead, Jasbir Arora (RSS) (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12767434.txt.

Description

Svetla Gadzhanova and Elizabeth Roughead measure how often biologic drugs fail for bowel disease in Australia. The drugs calm the immune system in Crohn's disease and ulcerative colitis, two long-term bowel illnesses. The team used a ten percent sample of national drug records. They tracked adults who started a biologic in 2019 or 2020 for twelve months.

For Crohn's disease, fifteen percent stopped their first drug by week sixteen. Rates split by drug, with one drug lowest and another highest. For colitis, a quarter stopped by week sixteen, again with wide gaps by drug. The authors name which drugs held patients longest in each illness. Such rates can guide first choices and plans for switching drugs.

Catalog record

CREATORSvetla Gadzhanova, Elizabeth Roughead, Jasbir Arora (RSS)
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE24 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12767434

Browse the full library · About the Tower of Babel